Vinva Investment Management Ltd Cuts Holdings in Kenvue Inc. (NYSE:KVUE)

Vinva Investment Management Ltd reduced its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 71.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,083 shares of the company's stock after selling 51,250 shares during the quarter. Vinva Investment Management Ltd's holdings in Kenvue were worth $467,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Van ECK Associates Corp boosted its position in Kenvue by 110.9% during the second quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company's stock worth $372,880,000 after purchasing an additional 10,783,258 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Kenvue by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company's stock valued at $789,813,000 after buying an additional 7,546,362 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock worth $2,011,832,000 after acquiring an additional 7,115,374 shares in the last quarter. American Century Companies Inc. raised its position in Kenvue by 20.7% during the second quarter. American Century Companies Inc. now owns 27,382,644 shares of the company's stock worth $497,816,000 after acquiring an additional 4,700,697 shares during the period. Finally, M&G PLC lifted its holdings in Kenvue by 538.0% during the third quarter. M&G PLC now owns 4,341,172 shares of the company's stock valued at $99,847,000 after purchasing an additional 3,660,730 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Down 0.2 %

NYSE KVUE traded down $0.05 during trading hours on Friday, reaching $24.08. The company had a trading volume of 7,516,546 shares, compared to its average volume of 14,280,981. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $46.17 billion, a P/E ratio of 43.78, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. The stock has a 50-day moving average of $22.94 and a 200 day moving average of $20.99. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm's quarterly revenue was down .4% on a year-over-year basis. During the same quarter last year, the company posted $0.31 EPS. As a group, research analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.41%. The ex-dividend date was Wednesday, November 13th. Kenvue's payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research reports. Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target on the stock. UBS Group raised their price objective on Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Bank of America raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.